{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:41:45Z","timestamp":1792615305326,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Advances"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jacadv.2026.102972","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T19:30:10Z","timestamp":1784748610000},"page":"102972","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P1","title":["Meta-Analysis of SGLT2 Inhibitors in Transthyretin Cardiac Amyloidosis"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-7717-8568","authenticated-orcid":false,"given":"Lorenzo","family":"Bianchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Marchionni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taras","family":"Chendey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9669-4278","authenticated-orcid":false,"given":"Stefano","family":"Benenati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2950-9058","authenticated-orcid":false,"given":"Andrea","family":"Minghini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Giannino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Cavolina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Soragni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Chimenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"39","key":"10.1016\/j.jacadv.2026.102972_bib1","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","volume":"44","author":"Marx","year":"2023","journal-title":"Eur Heart J"},{"issue":"36","key":"10.1016\/j.jacadv.2026.102972_bib2","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"issue":"4S","key":"10.1016\/j.jacadv.2026.102972_bib3","first-page":"S117","article-title":"KDIGO 2024 Clinical Practice Guideline for the evaluation and management of Chronic Kidney Disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"issue":"10354","key":"10.1016\/j.jacadv.2026.102972_bib4","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.jacadv.2026.102972_bib5","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2026.102972_bib6","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.jacadv.2026.102972_bib7","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.jacc.2024.03.429","article-title":"SGLT2 inhibitor therapy in patients with transthyretin amyloid Cardiomyopathy","volume":"83","author":"Porcari","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.jacadv.2026.102972_bib8","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1093\/ehjcvp\/pvaf033","article-title":"Tolerability and efficacy of sodium-glucose co-transporter 2 inhibitors in patients with cardiac amyloidosis: a meta-analysis of observational studies","volume":"11","author":"Laborante","year":"2025","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jacadv.2026.102972_bib9","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1001\/jamasurg.2021.0522","article-title":"MOOSE reporting guidelines for meta-analyses of observational studies","volume":"156","author":"Brooke","year":"2021","journal-title":"JAMA Surg"},{"key":"10.1016\/j.jacadv.2026.102972_bib10","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jacadv.2026.102972_bib11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample","volume":"5","author":"Hozo","year":"2005","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.jacadv.2026.102972_bib12","author":"Higgins"},{"key":"10.1016\/j.jacadv.2026.102972_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/hsr2.178","article-title":"Arcsine-based transformations for meta-analysis of proportions: pros, cons, and alternatives","volume":"3","author":"Lin","year":"2020","journal-title":"Health Sci Rep"},{"issue":"1","key":"10.1016\/j.jacadv.2026.102972_bib14","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ehf2.14188","article-title":"SGLT2 inhibitor therapy for transthyretin amyloid cardiomyopathy: early tolerance and clinical response to Dapagliflozin","volume":"10","author":"Dobner","year":"2023","journal-title":"ESC Heart Fail"},{"issue":"5","key":"10.1016\/j.jacadv.2026.102972_bib15","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jchf.2025.01.025","article-title":"Sodium-Glucose cotransporter 2 inhibitors in tafamidis-treated transthyretin amyloid cardiomyopathy: a contemporary real-world analysis","volume":"13","author":"Chi","year":"2025","journal-title":"JACC Heart Fail"},{"issue":"4","key":"10.1016\/j.jacadv.2026.102972_bib16","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/ejhf.3198","article-title":"Sodium-glucose cotransporter 2 inhibitors for transthyretin amyloid cardiomyopathy: analyses of short-term efficacy and safety","volume":"26","author":"Lang","year":"2024","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"10.1016\/j.jacadv.2026.102972_bib17","article-title":"Sodium-Glucose cotransporter 2 inhibitor use and outcomes in Transthyretin Amyloid Cardiomyopathy","volume":"3","author":"Jaiswal","year":"2024","journal-title":"JACC: Adv"},{"issue":"243","key":"10.1016\/j.jacadv.2026.102972_bib18","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.amjcard.2025.01.012","article-title":"Impact of sodium-glucose Cotransporter-2 inhibitors on cardiovascular outcomes in Transthyretin Amyloid Cardiomyopathy","volume":"15","author":"Byer","year":"2025","journal-title":"Am J Cardiol"},{"issue":"6","key":"10.1016\/j.jacadv.2026.102972_bib19","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.amjmed.2025.02.010","article-title":"Sodium-Glucose cotransporter 2 inhibitors in patients with amyloidosis with or without heart failure","volume":"138","author":"Augusto","year":"2025","journal-title":"Am J Med"},{"issue":"6","key":"10.1016\/j.jacadv.2026.102972_bib20","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.hrthm.2024.09.002","article-title":"Impact of SGLT2 inhibitors on the outcomes of patients with cardiac arrhythmias and Transthyretin Cardiac Amyloidosis","volume":"22","author":"Sivamurugan","year":"2025","journal-title":"Heart Rhythm"},{"issue":"3","key":"10.1016\/j.jacadv.2026.102972_bib21","doi-asserted-by":"crossref","DOI":"10.31083\/RCM26081","article-title":"Potential hematopoietic effects of SGLT2 inhibitors in patients with cardiac amyloidosis","volume":"26","author":"Ermolaev","year":"2025","journal-title":"Rev Cardiovasc Med"},{"issue":"4","key":"10.1016\/j.jacadv.2026.102972_bib22","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s11739-022-02944-8","article-title":"SGLT2i in patients with transthyretin cardiac amyloidosis, a well-tolerated option for heart failure treatment? Results from a small, real-world, patients series","volume":"17","author":"Zampieri","year":"2022","journal-title":"Intern Emerg Med"},{"issue":"1","key":"10.1016\/j.jacadv.2026.102972_bib23","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3390\/jcm13010283","article-title":"Safety and tolerability of SGLT2 inhibitors in cardiac Amyloidosis-A clinical feasibility study","volume":"13","author":"Steinhardt","year":"2024","journal-title":"J Clin Med"},{"issue":"10","key":"10.1016\/j.jacadv.2026.102972_bib24","article-title":"The role of sodium-glucose Cotransporter-2 inhibitors in adults with transthyretin cardiac amyloidosis: a single-center retrospective cohort Study","volume":"16","author":"Pillai","year":"2024","journal-title":"Cureus"},{"issue":"19","key":"10.1016\/j.jacadv.2026.102972_bib25","doi-asserted-by":"crossref","first-page":"5966","DOI":"10.3390\/jcm13195966","article-title":"Impact of SGLT2-Inhibitor therapy on survival in patients with transthyretin amyloid cardiomyopathy: analysis of a prospective registry Study","volume":"13","author":"Schwegel","year":"2024","journal-title":"J Clin Med"},{"issue":"4","key":"10.1016\/j.jacadv.2026.102972_bib26","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.recesp.2023.10.007","article-title":"Use of SGLT2i in patients with transthyretin amyloid cardiomyopathy: prevalence and safety in a Spanish prospective cohort","volume":"77","author":"Gonz\u00e1lez-Montes","year":"2024","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"10254","key":"10.1016\/j.jacadv.2026.102972_bib27","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jacadv.2026.102972_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1273781","article-title":"Efficacy and safety of sodium-glucose cotransporter-2 inhibitors for heart failure with mildly reduced or preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Cheema","year":"2023","journal-title":"Front Cardiovasc Med"},{"issue":"12","key":"10.1016\/j.jacadv.2026.102972_bib29","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"issue":"31","key":"10.1016\/j.jacadv.2026.102972_bib30","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehad347","article-title":"Conventional heart failure therapy in cardiac ATTR amyloidosis","volume":"44","author":"Ioannou","year":"2023","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.jacadv.2026.102972_bib31","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","article-title":"Mechanisms of cardiovascular benefits of Sodium Glucose Co-Transporter 2 (SGLT2) inhibitors: a state-of-the-art review","volume":"5","author":"Lopaschuk","year":"2020","journal-title":"JACC Basic Transl Sci"},{"issue":"11","key":"10.1016\/j.jacadv.2026.102972_bib32","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid Cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"}],"container-title":["JACC: Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X26003935?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X26003935?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:54:53Z","timestamp":1792612493000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X26003935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2772963X26003935"],"URL":"https:\/\/doi.org\/10.1016\/j.jacadv.2026.102972","relation":{},"ISSN":["2772-963X"],"issn-type":[{"value":"2772-963X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Meta-Analysis of SGLT2 Inhibitors in Transthyretin Cardiac Amyloidosis","name":"articletitle","label":"Article Title"},{"value":"JACC: Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2026.102972","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"102972"}}